International study of primary mucinous ovarian carcinomas managed at tertiary medical centers Journal Article
| Authors: | Mueller, J. J.; Lajer, H.; Mosgaard, B. J.; Bach Hamba, S.; Morice, P.; Gouy, S.; Hussein, Y.; Soslow, R. A.; Schlappe, B. A.; Zhou, Q. C.; Iasonos, A.; Høgdall, C.; Leary, A.; O'Cearbhaill, R. E.; Abu-Rustum, N. R. |
| Article Title: | International study of primary mucinous ovarian carcinomas managed at tertiary medical centers |
| Abstract: | Objective We sought to describe a large, international cohort of patients diagnosed with primary mucinous ovarian carcinoma (PMOC) across 3 tertiary medical centers to evaluate differences in patient characteristics, surgical/adjuvant treatment strategies, and oncologic outcomes. Methods This was a retrospective review spanning 1976-2014. All tumors were centrally reviewed by an expert gynecologic pathologist. Each center used a combination of clinical and histologic criteria to confirm a PMOC diagnosis. Data were abstracted from medical records, and a deidentified dataset was compiled and processed at a single institution. Appropriate statistical tests were performed. Results Two hundred twenty-two patients with PMOC were identified; all had undergone primary surgery. Disease stage distribution was as follows: stage I, 163 patients (74%); stage II, 8 (4%); stage III, 40 (18%); and stage IV, 10 (5%). Ninety-nine (45%) of 219 patients underwent lymphadenectomy; 41 (19%) of 215 underwent fertility-preserving surgery. Of the 145 patients (65%) with available treatment data, 68 (47%) had received chemotherapy - 55 (81%) a gynecologic regimen and 13 (19%) a gastrointestinal regimen. The 5-year progression-free survival (PFS) rates were 80% (95% confidence interval [CI], 73%-85%) for patients with stage I to II disease and 17% (95% CI, 8%-29%) for those with stage III to IV disease. The 5-year PFS rate was 73% (95% CI, 50%-86%) for patients who underwent fertility-preserving surgery. Conclusions Most patients (74%) presented with stage I disease. Nearly 50% were treated with adjuvant chemotherapy using various regimens across institutions. The PFS outcomes were favorable for those with early-stage disease and lower but acceptable for those who underwent fertility preservation. © 2018 by IGCS and ESGO. |
| Keywords: | survival; ovarian cancer; fertility preservation; primary mucinous ovarian cancer |
| Journal Title: | International Journal of Gynecological Cancer |
| Volume: | 28 |
| Issue: | 5 |
| ISSN: | 1048-891X |
| Publisher: | Lippincott Williams & Wilkins |
| Date Published: | 2018-06-01 |
| Start Page: | 915 |
| End Page: | 924 |
| Language: | English |
| DOI: | 10.1097/igc.0000000000001263 |
| PROVIDER: | scopus |
| PMCID: | PMC5962416 |
| PUBMED: | 29561302 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 2 July 2018 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
-
888Abu-Rustum -
253Zhou -
362Iasonos -
271O'Cearbhaill -
793Soslow -
45Hussein -
186Mueller -
19
Schlappe
Related MSK Work